Clinical Trial Search

Primary: Percentage of Cancer Participants With Breakthrough Cancer Pain From the Total Number of Cancer Participants Seen in Consultation — 14.3 percentage of participants

Primary: Summed Pain Intensity Differences (SPID) at 30 Minutes After Dosing (SPID30) — 640.3; 399.6 Units on a scale

Primary: Percentage of Participants With Adverse Events. — 88.5 percentage of participants

Primary: Pain Intensity Difference (PID) at 15 Minutes Post-treatment (PID15) — 0.88; 0.76 Units on scale — p=0.0004

Primary: Summary of Pain Intensity Differences (SPID) — 47.9; 38.1 Score on a scale — p=0.004

Primary: Retention Rate — 100; 100 percentage of participants

Primary: Pain Intensity Difference (PID15) At 15 Minutes — 0.82; 0.59 Units on a scale — p=<0.0001

Primary: Change From Baseline in the Numerical Rating Pain Scale (NRS) — 1.87; 1.81 units on a scale

Primary: Time-weighted SPID30 — 59.9; 42.6 units on a scale — p=<0.001

Primary: Feasibility - Pain Consultation — 29 Participants

Primary: Dyspnea Numeric Rating Scale — -2.4; -1.1 score on a scale

Primary: Dose of Instanyl — 75; 30; 50; 69 participants

Primary: Percentage of Patients That Experienced 1 or More Adverse Events — 59.0; 80.7 Percentage of patients

Primary: Proportion of Non-Responder (NR) Participants — 14; 18; 14; 11 participants

Primary: Numerical Rating Scale (NRS) — 3.91; 3.87 scores on a scale

Primary: Change in Neuropathic Pain Score at 2 Months (Numeric Rating Scale 0-10) — 4.1; 4.6 units on a scale

Primary: Improvement of Pain. — 3 score on a scale (0-10)

Primary: Percent Improvement From Baseline In Mean NRS Average Pain At End Of Treatment — 10.7; 4.5 percent improvement — p=0.0854

Primary: Percent Improvement From Baseline In Mean NRS Average Pain At End Of Treatment — 7.2; 9.5 percent improvement — p=0.2735

Primary: Number of Subjects With Success Rate at 15 Minutes Post-epidural Bolus Injection — 31; 38 Participants — p=0.38

Primary: Modified Dyspnea Borg Scale (Dyspnea Intensity) — -1.4; -0.5 score on a scale

Primary: Pain Intensity — 5.60; 6.44; 5.11; 5.98 units on a scale

Primary: Analgesic Adherence-patient — 0.66; 0.67 proportion (0-1), higher is better — p=.43

Primary: Change From Randomization Baseline In Mean NRS Average Pain At End Of Treatment — 0.5; 0.5 units on a scale — p=0.9173

Primary: Average Pain Intensity Score — 1.192; 1.304 units on a scale

Primary: The Number of Subjects Who Achieve at Least a 30 Percent Decrease in Pain From Baseline in VAS Pain Score Calculated From BPI Questionnaire. — 8 Participants

Primary: The Number of Subjects With Ineffective Treatment During the Double-blind Evaluation Phase. — 89; 66; 155; 81 participants — p=.0217

Primary: Patient's Change From Baseline of Pain Severity, as Measured by the Weekly Means of the Daily Average Pain Scores (APS) — 2.26 units on a scale

Primary: Dyspnea Numeric Rating Scale — -2.0; -1.7; -2.3; -2.5 score on a scale

Primary: Efficacy Was Not Measured in This Study. The Number of Deaths in the Long Term Follow-up Will be Reported. — 0 Participants